Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from University of Ljubljana have provided new data on breast cancer
October 9th, 2008
"The aim of this study was to investigate the potential protective role of fullerenol C-60(OH)(24) on doxorubicin-induced liver toxicity using in vivo (female Sprague-Dawley rats) and in vitro (human hepatocellular carcinoma - HepG2; colorectal adenocarcinoma cell lines - Caco-2) approaches. The first (healthy control) and second (control with chemically induced mammary carcinomas) group received saline only," scientists in Ljubljana, Slovenia report. "The third, fourth and fifth group (all with breast cancer) were injected (i.p.) with a single dose of doxorubicin (8 mg/kg), doxorubicin/fullerenol (100 mg/kg of fullerenol 30 min before administration of 8 mg/kg...
Source: Women's Health Weekly (2008-10-09)
|
